PFM Health Sciences, LP 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
PFM Health Sciences, LP | 345,926 0.700% |
-3,626,942 (-91.29%) |
Filing |
| 2022-02-14 12:37 pm Purchase |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
PFM Health Sciences, LP | 3,972,868 7.800% |
1,584,801 (+66.36%) |
Filing |
| 2021-02-01 2:13 pm Purchase |
2021-01-20 | 13G | Jounce Therapeutics, Inc. JNCE |
PFM Health Sciences, LP | 2,388,067 6.000% |
2,388,067 (New Position) |
Filing |